Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BCD-085 (Netakimab) in Healthy Volunteers
NCT02380287Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Mar 2015
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of netakimab in psoriasis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 1 more (8 cohorts), sponsored by BIOCAD. Primary endpoint: Area Under the Plasma Concentration-Time Curve. Started Mar 2015; status: completed.
02
Drugs
netakimab
03
Conditions
psoriasisrheumatoid arthritis (RA)systemic lupus erythematosus (SLE)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02380287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380287.